Evidence map›Paper›PMID 32061771›Full record

ArticleBiochemical pharmacology2020

NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS.

Mitali Chattopadhyay, Ravinder Kodela, Gabriela Santiago, Thuy Tien C Le, Niharika Nath, Khosrow Kashfi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. The Triple Crown: NO, CO, and HPharmacology & therapeutics · 2023
    Review
  8. Anticancer and Anti-Inflammatory Mechanisms of NOSH-Aspirin and Its Biological Effects.Computational and mathematical methods in medicine · 2022
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Mitali ChattopadhyayDepartment of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY, United States.
Ravinder KodelaDepartment of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY, United States.
Gabriela SantiagoDepartment of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY, United States.
Thuy Tien C LeDepartment of Biological and Chemical Sciences, New York Institute of Technology, NY 10023, United States.
Niharika NathDepartment of Biological and Chemical Sciences, New York Institute of Technology, NY 10023, United States.
Khosrow KashfiDepartment of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY, United States; Avicenna Pharmaceuticals Inc., New York NY, United States; Graduate Program in Biology, City University of New York Graduate Center, New York NY, United States. Electronic address: kashfi@med.cuny.edu.
City University of New York · USNew York Institute of Technology · USThe Graduate Center, CUNY · US

Funding

MIDARP at CCNYR24DA018055 · NIDA · CITY COLLEGE OF NEW YORK · PI FRIEDMAN, EITAN · 2005 to 2010
$2.2M
NIDA NIH HHS R24 DA018055
6 · The paper itself

Abstract

Pancreatic cancer has poor survival rates and largely ineffective therapies. Aspirin is the prototypical anti-cancer agent but its long-term use is associated with significant side effects. NOSH-aspirin belongs to a new class of anti-inflammatory agents that were designed to be safer alternatives by releasing nitric oxide and hydrogen sulfide. In this study we evaluated the effects of NOSH-aspirin against pancreatic cancer using cell lines and a xenograft mouse model. NOSH-aspirin inhibited growth of MIA PaCa-2 and BxPC-3 pancreatic cancer cells with IC

Indexed as

Xenograft Model Antitumor AssaysAnimalsAspirinCaspase 3Cell Line, TumorCell ProliferationDisulfidesForkhead Box Protein M1MaleMice, NudeMice, SCIDNF-kappa BNitratesNitric Oxide Synthase Type IIPancreatic NeoplasmsReactive Oxygen Species4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4-(nitrooxy)butanoyl)oxy)benzoateAspirinCaspase 3DisulfidesForkhead Box Protein M1NF-kappa BNitratesNitric Oxide Synthase Type IIReactive Oxygen SpeciesCell kineticsCell signalingFoxM1Hydrogen sulfideNitric oxideNOSH-aspirinp53Pancreatic cancerReactive oxygen species

Identifiers

PMID32061771
PMCPMC7263941
OpenAlexW3005930759

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.